Fujian Haixi Pharmaceuticals Co., Ltd. (“Haixi Pharma,” Stock Code: 2637) has finalized its Global Offering of 11,500,000 H Shares at HK$86.40 per H Share. The Shares are set to commence trading on October 20, 2025, in board lots of 50 H Shares each.

According to official data, the Hong Kong Public Offering totaled 1,150,000 H Shares, oversubscribed 3,165.1 times, while the International Offering of 10,350,000 H Shares recorded a subscription multiple of 6.3. Based on the Final Offer Price, the listing is expected to generate gross proceeds of approximately HK$993.60 million, with estimated net proceeds of HK$940.13 million.

Allotment results show 316,139 valid Hong Kong Public Offer applications, and 46 placees under the International Offering. One cornerstone investor was allocated 1,981,700 H Shares (17.23% of the total Offer Shares), representing 2.52% of Haixi Pharma's total issued share capital upon listing.

Lock-up arrangements apply to existing shareholders, including the controlling shareholders, for periods of either six months or a year from the listing date in accordance with applicable regulations. Immediately following completion of the Global Offering, the shares counted toward the public float represent approximately 26.72% of the total H Shares.

Dealings in the company’s H Shares on the Stock Exchange are scheduled to begin at 9:00 a.m. on October 20, 2025. The company’s final stock short name will be “HAIXI PHARMA,” with the stock code “2637.”